These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30742620)

  • 1. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J; den Boer ML; Essink DR; Ritmeijer K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
    Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
    Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
    Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
    Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
    Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
    Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 16. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
    Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
    Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment.
    Maruf S; Nath P; Islam MR; Aktar F; Anuwarul A; Mondal D; Basher A
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006781. PubMed ID: 30222747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.